Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

FDA Approves Quetiapine for Maintenance Treatment in Bipolar Disorder WASHINGTON, DC -- May 14, 2008 -- AstraZeneca announced today that the United States Food and Drug Administration (FDA) has approved quetiapine fumarate (Seroquel) for the maintenance treatment of patients with bipolar I disorder, as adjunct to lithium or divalproex. Quetiapine is approved by the FDA for the treatment of schizophrenia, and is also the only single agent approved by the FDA for the treatment of both depressive and acute manic episodes associated with bipolar disorder. The FDA approval was based on 2 multicentre, randomised, double-blind, placebo-controlled clinical trials which are part of the clinical trial program known as BOLDER (Bipolar Depression). These 2 studies evaluated quetiapine when used as an adjunct therapy to lithium or divalproex in the maintenance treatment of adults with bipolar I disorder (n = 703, n = 623, respectively). The rigourous study design included a 12- to 36-week stabilisation phase which was followed by up to 2 years of randomised, double-blind treatment (mean duration of quetiapine treatment was 189 and 240 days, respectively). In both studies, patients with bipolar I disorder whose most recent episode was manic, depressed, or mixed were treated with either quetiapine (flexible dosing between 400 mg and 800 mg per day in divided doses) plus lithium or divalproex, or placebo plus lithium or divalproex. The primary endpoint -- time to recurrence of a depressive, manic, or mixed-mood event -- was significant for quetiapine compared with placebo in both studies. Pooled study results indicated that patients treated with quetiapine plus lithium or divalproex had a risk reduction of 70% relative to those in the placebo arm for time to recurrence of a mood event (hazard ratio [HR]: 0.30; 95% confidence interval [CI]: 0.24-0.37; P < .001). This reduction in risk was significant for both recurrence of manic episodes (HR: 0.30; 95% CI: 0.22-0.41; P < .001) and recurrence of depressive episodes (HR: 0.30; 95% CI: 0.23-0.40; P < .001). The proportion of patients who relapsed when treated with quetiapine was 19.3% (125/646) versus 50.4% (343/680) of patients on placebo. Source: AstraZeneca E-mail this page to a friend or colleague! To print, use this version